Jason Shafrin, PhD

Healthcare Economist

12/20/2021

Jason Shafrin, PhD, discusses a paper examining how prices vary for branded, physician-administered drugs which had generic or biosimilar versions introduced before 2005.

Jason Shafrin, PhD, discusses a...

12/20/2021

Journal of Clinical Pathways

Guest Blog

Has Medicine Reached the Digital Age? Five Key Obstacles Digital Technologies Still Need to Overcome

08/26/2021

Jason Shafrin , PhD;

Jason Shafrin, PhD, and David Gruber, MD, MBA, discuss challenges digital health innovators face and what digital health technologies must provide to be successful.

Jason Shafrin, PhD, and David...

08/26/2021

Journal of Clinical Pathways

Healthcare Economist

Which Strategies Are Payers and Employers Using to Cover Ophan Drugs?

06/20/2021

Jason Shafrin , PhD;

Jason Shafrin, PhD, discusses a survey which explored affordability challenges posed by orphan drugs from the payer, provider, and employer perspectives.

Jason Shafrin, PhD, discusses a...

06/20/2021

Journal of Clinical Pathways

Healthcare Economist

The Real Cost of Electronic Health Records

06/07/2021

Jason Shafrin , PhD;

Jason Shafrin, PhD, discusses the many cost aspects of successfully implementing electronic health records.

Jason Shafrin, PhD, discusses...

06/07/2021

Journal of Clinical Pathways

Healthcare Economist

Impact of COVID-19 on CMS’ Value-Based Programs

06/01/2021

Jason Shafrin , PhD;

Jason Shafrin, PhD, discusses the effect quality impacts during COVID-19 will have on Medicare reimbursement to providers through 2024.

Jason Shafrin, PhD, discusses...

06/01/2021

Journal of Clinical Pathways

Pharma Insights

Does COVID-19 Threaten the Progress Pharmaceuticals Have Made in Reducing Cancer Mortality Over the Last 20 Years?

12/16/2020

Farzad Ali , BPharm, MS;

Joanna P. MacEwan , PhD;

Jason Shafrin , PhD;

The development and introduction of new pharmaceuticals has played a pivotal role in reducing US cancer deaths. While pharmaceuticals have played a significant role in reducing cancer mortality, winning the war on...

The...

12/16/2020

Journal of Clinical Pathways

Pharma Insights

Open-Source Tools for Value Assessment: A Promising Approach

06/14/2018

Jason Shafrin , PhD;

Jennifer Bright , MPA;

Mark T. Linthicum , MPP;

While many advancements have been made thus far in the progression toward value-based health care, there are persistent challenges in the measurement of value. In order to deliver value-based care, health care...

While...

06/14/2018

Journal of Clinical Pathways

Pharma Insights

The Clash: Treatment Advances and Value Measurements in Oncology

04/11/2017

Jason Shafrin , PhD;

Larry Blandford , PharmD;

Cancer has or will affect nearly every person at some point in their lives, either directly or indirectly. The fight against cancer is central to society; in recent years, treatment advances and prevention strategies...

Cancer...

04/11/2017

Journal of Clinical Pathways